

BD Receives FDA Clearance for New Syringe Designed for the Administration of Humulin® R U-500 Insulin

FRANKLIN LAKES, N.J., August 15, 2016 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its new syringe for patients using Humulin R U-500 insulin vials. Humulin R U-500 insulin is indicated for patients with diabetes requiring more than 200 units of insulin per day. Compared to syringes made for U-100 insulin, the new BD U-500 Insulin Syringe is designed to make it easier for patients and health care providers to draw the correct dose of U-500 insulin by reducing steps that can result in dosing errors.

"BD is committed to advancing the world of health through innovative products which promote patient safety. FDA clearance of the BD U-500 Insulin Syringe is a positive step forward for both health care providers and patients who previously relied on manually converting U-500 insulin doses to the appropriate dose or volume, when using a U-100 insulin syringe," said Ken Miller, worldwide president of Diabetes Care for BD. "With the new syringe, dose conversion is no longer needed, which helps reduce potential medication errors by both patients and health care providers."

The BD U-500 Insulin Syringe is the first and only insulin syringe developed for patients taking Humulin R U-500 insulin. The BD U-500 Insulin Syringe features a 6mm x 31G syringe needle, the shortest insulin syringe needle available today, which is designed to deliver insulin injections into the subcutaneous tissue while minimizing the risk of intramuscular injection. The BD U-500 Insulin Syringe also has clearly marked dosage labeling designed to distinguish between other syringes, to help prevent confusion and incorrect dosing. The new insulin syringe is a 0.5mL syringe with clear, bold U-500 scale markings in 5 unit increments and allows for dosing up to 250 units. The syringe package and components are color coded to align with the Humulin-R U-500 insulin green and aqua color scheme.

The BD U-500 Insulin Syringe for use with Humulin R U-500 insulin vials will be available by prescription only. Commercial availability is planned for November 2016.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com

For more information on BD, please visit bd.com.

Matthew Coppola

201 847 7370

[Email](#)

Monique N. Dolecki

201 847 5378

[Email](#)

<https://news.bd.com/2016-08-15-BD-Receives-FDA-Clearance-for-New-Syringe-Designed-for-the-Administration-of-Humulin-R-R-U-500-Insulin>